公众号 / 文章复苏、休克与脓毒症重症综合管理与镇静镇痛消化、代谢与肾脏急症

脓毒症相关弥散性血管内凝血的病理生理、诊断与治疗

The pathophysiology, diagnosis, and management of sepsis-associated disseminated intravascular coagulation.
PubMed 文献 · J Intensive Care · 2023-05-23
一句话结论推荐用SIC评分系统筛查和监测脓毒症相关DIC,但除控制感染外,肝素、抗凝血酶、重组血栓调节蛋白的疗效尚待未来临床研究证实。

本文综述脓毒症相关弥散性血管内凝血(DIC)的病理生理、诊断与治疗。ISTH于2001年发布显性DIC诊断标准,将DIC视为终末期消耗性凝血病而非治疗靶点;2019年又推出脓毒症诱导凝血病(SIC)标准,仅需血小板计数、凝血酶原时间-国际标准化比值和序贯器官衰竭评估评分,可诊断代偿期凝血病。脓毒症相关DIC病理生理为多因素,除凝血激活伴纤溶抑制外,活化白细胞、血小板和血管内皮细胞启动多重炎症反应,构成血栓炎症。治疗上除控制感染外缺乏特异性方法,既往临床试验因纳入非凝血病患者而失败,肝素、抗凝血酶和重组血栓调节蛋白的疗效尚待未来临床研究证实。作者推荐用SIC评分系统筛查和监测DIC。

要点

  • ISTH于2019年推出SIC标准,仅需血小板计数、凝血酶原时间-国际标准化比值和序贯器官衰竭评估评分,可诊断代偿期凝血病。
  • SIC评分可用于评估疾病严重程度并确定潜在治疗干预的时机。
  • 脓毒症相关DIC的病理生理为多因素,除凝血激活伴纤溶抑制外,还包括活化白细胞、血小板和血管内皮细胞启动的多重炎症反应(血栓炎症)。
  • 除控制感染外,脓毒症相关DIC缺乏特异性治疗;既往临床试验因纳入非凝血病患者而失败。
  • 作者推荐用SIC评分系统筛查和监测DIC;肝素、抗凝血酶和重组血栓调节蛋白的疗效尚待未来临床研究证实。

适用人群与场景

  • 脓毒症患者,脓毒症是DIC最常见的基础疾病。
  • DIC可由多种危重病引起,但本文聚焦脓毒症相关DIC。

诊断标准与关键阈值

  • ISTH于2001年发布显性DIC诊断标准,用于诊断DIC晚期阶段。
  • ISTH于2019年推出SIC标准,用于诊断代偿期凝血病,仅需血小板计数、凝血酶原时间-国际标准化比值和序贯器官衰竭评估评分。
  • SIC评分可用于评估疾病严重程度并确定潜在治疗干预的时机。

处置流程与药物剂量

  • 治疗基础感染是脓毒症相关DIC治疗的基础,除此之外缺乏特异性治疗手段。
  • 除感染控制外,抗凝治疗将是脓毒症相关DIC的选择。
  • 肝素、抗凝血酶和重组血栓调节蛋白的疗效尚待未来临床研究证实。
  • 作者推荐用SIC评分系统筛查和监测DIC。

研究设计与关键结果

  • 本文为综述,指出DIC不再仅被视为终末期消耗性凝血病,而是包括凝血系统激活的早期阶段。
  • 脓毒症相关DIC的病理生理为多因素,包括凝血激活伴纤溶抑制,以及活化白细胞、血小板和血管内皮细胞启动的多重炎症反应(血栓炎症)。
  • 既往临床试验因纳入非凝血病患者而失败。

证据类型、等级与局限

  • 证据类型:综述。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对脓毒症患者,可用SIC评分系统(血小板计数、凝血酶原时间-国际标准化比值、序贯器官衰竭评估评分)筛查和监测DIC,以评估疾病严重程度并确定潜在治疗干预的时机(作者推荐)。
  • 脓毒症相关DIC的治疗以控制感染为基础,抗凝治疗(肝素、抗凝血酶、重组血栓调节蛋白)的疗效尚待未来临床研究证实,不能据此常规使用。

指南或共识出处

  • 国际血栓与止血学会(ISTH)2001年显性DIC诊断标准。
  • 国际血栓与止血学会(ISTH)2019年脓毒症诱导凝血病(SIC)标准。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: The International Society on Thrombosis and Haemostasis (ISTH) released overt disseminated intravascular coagulation (DIC) diagnostic criteria in 2001. Since then, DIC has been understood as the end-stage consumptive coagulopathy and not the therapeutic target. However, DIC is not merely a decompensated coagulation disorder, but also includes early stages with systemic activation in coagulation. Thus, the ISTH has recently released sepsis-induced coagulopathy (SIC) criteria that can diagnose compensated-phase of coagulopathy with readily available biomarkers.

MAIN BODY: DIC is a laboratory-based diagnosis due to various critical conditions, although sepsis is the most common underlying disease. The pathophysiology of sepsis-associated DIC is multifactorial, and in addition to coagulation activation with suppressed fibrinolysis, multiple inflammatory responses are initiated by activated leukocytes, platelets, and vascular endothelial cells as part of thromboinflammation. Although overt DIC diagnostic criteria were established by ISTH to diagnose the advanced stage of DIC, additional criteria that can detect an earlier stage of DIC were needed for potential therapeutic considerations. Accordingly, the ISTH introduced SIC criteria in 2019 that are easy to use and require only platelet count, prothrombin time-international normalized ratio, and Sequential Organ Failure Assessment Score. SIC score can be used to evaluate disease severity and determine the timing of potential therapeutic interventions. One of the major disadvantages in treating sepsis-associated DIC is the lack of availability of specific therapeutic approaches beyond treating the underlying infection. Clinical trials to date have failed because included patients who were not coagulopathic. Nevertheless, in addition to infection control, anticoagulant therapy will be the choice for sepsis-associated DIC. Therefore, the efficacy of heparin, antithrombin, and recombinant thrombomodulin has to be proven in future clinical studies.

CONCLUSION: It is necessary to develop a novel therapeutic strategy against sepsis-associated DIC and improve the outcomes. Consequently, we recommend screening and monitoring DIC using SIC scoring system.

来源:J Intensive Care,查看原文。版权归原作者所有。

参考来源

  1. Iba T, Helms J, Connors JM, et al. The pathophysiology, diagnosis, and management of sepsis-associated disseminated intravascular coagulation. J Intensive Care. 2023. PMID: 37221630. doi:10.1186/s40560-023-00672-5

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。